Ensol Biosciences Inc. Logo

Ensol Biosciences Inc.

AI-driven biopharma developing peptide drugs for unmet medical needs.

140610 | KO

Overview

Corporate Details

ISIN(s):
KR7140610007
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노10로 51(탑립동), 대전광역시

Description

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean HTML 4.2 KB
2025-08-08 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 66.6 KB
2025-08-08 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.4 KB
2025-08-06 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 67.6 KB
2025-08-06 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 26.8 KB
2025-07-31 00:00
증권발행결과(자율공시)
Korean HTML 5.1 KB
2025-07-22 00:00
주요사항보고서(유상증자결정)
Korean HTML 38.5 KB
2025-07-21 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 66.3 KB
2025-07-21 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.4 KB
2025-07-18 00:00
증권발행결과(자율공시)
Korean HTML 5.1 KB
2025-07-10 00:00
주요사항보고서(유상증자결정)
Korean HTML 31.0 KB
2025-06-12 00:00
최대주주변경
Korean HTML 22.0 KB
2025-06-12 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 84.8 KB
2025-06-11 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 67.9 KB
2025-06-11 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.8 KB

Automate Your Workflow. Get a real-time feed of all Ensol Biosciences Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ensol Biosciences Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ensol Biosciences Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.